Novartis AG
As of Oct 22, 2026, Novartis is in Stage 4, the downtrend phase, now in week 3 (since Oct 7, 2026). It closed at $156.27, 4.5% below its 52-week high and above its 200-day average, which is rising.
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is NVS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
NVS among Drug Manufacturers - General11th of 21 by relative strength
All 21 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | MRK | Stage 2 · wk 16 | 92 | −0.6% |
| 2 | BIIB | Stage 2 · wk 21 | 92 | +11.6% |
| 3 | LLY | Stage 2 · wk 1 | 90 | +13.5% |
| 4 | AMGN | Stage 2 · wk 16 | 87 | +10.1% |
| 5 | OGN | Stage 2 · wk 23 | 87 | +0.1% |
| 6 | BMY | Stage 3 · wk 1 | 85 | +4.1% |
| 7 | JNJ | Stage 2 · wk 16 | 83 | −0.6% |
| 8 | PFE | Stage 2 · wk 8 | 77 | +7.9% |
| …11 | NVS | Stage 4 · wk 3 | 72 | +9.5% |
Novartis: quick answers
What stage is Novartis in?
As of Oct 22, 2026, Novartis (NVS) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 7, 2026 and is in week 3. What the four stages mean
Is Novartis in an uptrend?
No. Novartis is in a Stage 4 downtrend. It trades 3.9% above its 200-day average, which is rising.
How far is Novartis from its 52-week high?
Novartis closed at $156.27 on Oct 22, 2026, 4.5% below its 52-week high of $163.64. Its 52-week low is $118.20.
How has Novartis performed over the past year?
As of Oct 22, 2026, Novartis is up 22.6% over the past year and up 16.2% so far in 2026.
Which sector and industry is Novartis in?
Novartis is in the Drug Manufacturers - General industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - General
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still?s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.